7th World CNS Summit
Targeting Neurodegenrative Diseases
Seaport Hotel & World Trade Center
February 19-21, 2019

Boston, MA, USA

 

The BD&L Summit for Life Sciences
Hyatt Centric Fisherman's Wharf

February 25-26, 2019
San Francisco, CA, USA


AD/PD 2019
March 26-31, 2019

Lisbon, Portugal


About Origenis

Origenis is a leader in small molecule drug discovery with over 15 years of experience in the field. Origenis is a privately owned company based in Martinsried, Germany.

Origenis runs its own patented Drug Discovery platform MOREsystem┬«. The unique platform combines state-of-the-art drug design, patent analysis, chemical synthesis and biological characterization performed in an integrated manner on 20.000 square feet of integrated lab space.

Origenis runs research alliances as well as active in-house programs. Origenis is currently focussing on anti-inflammatory and CNS drugs. Origenis is offering a variety of early out-licensing opportunities.

Origenis offers access to its proprietary patent database Cippix® - www.cippix.com.